CTOs on the Move

PhiloMetron Inc

www.philometron.com

 
PhiloMetron Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Clinical Research Dental Supplies and Services

Founded in 1985, Clinical Research Dental is the proud Canadian distributor for a number of internationally renowned dental manufacturers, including Clinician`s Choice, Ultradent, Bioclear, 3M, Cosmedent, Triodent, Komet and Ribbond. The company is also a leading provider of continuing education programs for dentists, and hosts 40 to 50 seminars and hands-on courses across Canada each year.

Vestergaard Frandsen

Vestergaard Frandsen is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ReSound

At ReSound, people with hearing loss are at the heart of everything we do. We think big and challenge the norm, because we believe Smart Hearing has the power to transform lives. Our award-winning Smart Hearing aids help people feel more involved, connected and in control. They deliver the best sound quality and optimal design. Smart Hearing aids also work like wireless stereo headphones, streaming sound directly to the hearing aids from devices like an iPhone® or a TV. An accompanying app gives full control and the ability to personalize each hearing experience. ReSound hearing aids are exclusively available through hearing care professionals, who adjust them to each individual`s specific hearing loss. With research teams in USA and Holland, we are headquartered in Denmark. ReSound is part of the GN Group, pioneering great sound from world leading ReSound hearing aids to Jabra office headsets and sports headphones. Founded in 1869, building on a strong legacy of innovative audio and communications solutuions, and listed on NSDAQ OMX Copenhagen, GN makes life sound better.

Tearlab

TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.

Palette Life Sciences

Palette Life Sciences is a fully integrated medical device company providing a wide range of products and services that improve quality of life of patients. Our portfolio of products focuses on treating conditions in urology/urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. For physicians, researchers, and inventors alike, progress begins with a natural curiosity and the drive to do more. By discovering and applying new applications of proven medicine to uncommon, or difficult to treat conditions, we can address the needs of patients often overlooked by traditional medical companies. Inspired by innovation and empathy, we see endless possibilities in expanding on proven technologies to elevate patient care. The foundation for all of our breakthrough products is Non-Animal Stabilized Hyaluronic Acid (NASHA®). NASHA has been proven safe and effective for more than two decades in over 50 million medical procedures worldwide. Barrigel® - the first and only FDA-cleared hyaluronic acid rectal spacer, minimizing the side effects of radiation therapy for prostate cancer patients. Barrigel is available in the US, Australia and Europe. Deflux® - the only FDA-approved injectable treatment for vesicoureteral reflux (VUR), a urinary defect that affects 1% of children worldwide. Deflux for VUR is available in the US, Canada, Europe, Japan, Latin America, Australia and New Zealand. Also indicated for stress urinary incontinence (SUI) in women, Deflux for SUI is available in Canada and Europe.